Generic Name and Formulations:
Lepirudin 50mg/vial; pwd for IV inj or infusion after reconstitution and dilution; contains mannitol.
Indications for REFLUDAN:
Heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease.
Do not start treatment if baseline aPTT ratio ≥2.5 to avoid initial overdosing. ≤110kg: Initially 0.4mg/kg by slow IV bolus inj over 15–20 seconds, follow by 0.15mg/kg/hour as a continuous IV infusion for 2–10 days or longer if clinically needed. >110kg: max initial bolus dose 44mg; max initial infusion dose 16.5mg/hour. Adjust dose based on aPTT ratio; usual target range (1.5–2.5). Monitor 1st aPTT determination at 4 hours after start of infusion and at least once daily during therapy; more frequently with renal impairment or serious liver injury. Dose adjustments, renal impairment, concomitant thrombolytic therapy: see literature.
Recent puncture or anomaly of vessels or organs. Recent cerebrovascular accident, stroke, intracerebral surgery, or other neuraxail procedures. Severe uncontrolled hypertension. Bacterial endocarditis. Hemorrhagic diathesis. Recent major surgery or major bleeding (eg, intracranial, GI, intraocular, or pulmonary). Active peptic ulcer. Advanced renal impairment. Monitor aPTT ratio and creatinine clearance prior to and during therapy. Hepatic impairment. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concomitant thrombolytics (eg, rt-PA, streptokinase), drugs that affect platelets, coumarin derivatives: increase risk of bleeding and potentiate effect of lepirudin on aPTT prolongation.
Direct thrombin inhibitor (recombinant hirudin).
Bleeding, abnormal liver function, anaphylactic reactions (esp with re-exposure; may be fatal), multiorgan failure, antibody formation.
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
- Direct-to-Consumer Genetic Test for Select BRCA Mutations Gets FDA Nod
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|